Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Korean Journal of Urology ; : 515-519, 2008.
Artículo en Coreano | WPRIM | ID: wpr-104938

RESUMEN

PURPOSE: Several studies have shown that finasteride limits hematuria in patients with benign prostatic hyperplasia(BPH). However, there are few reports addressing dutasteride therapy. We evaluated the effect of dutasteride on intraoperative blood loss and on microvessel density(MVD) in patients with BPH. MATERIALS AND METHODS: We studied 39 patients with BPH who underwent transurethral resection of the prostate(TURP). Group I included 22 patients who received dutasteride 0.5mg daily for 2 weeks preoperatively, and group II included 17 patients who did not. Blood loss was evaluated by comparing preoperative and postoperative hemoglobin. Sections from the prostatic suburothelium and hyperplastic prostate were individually stained for CD 34. MVD was calculated by counting the number of positively stained blood vessels in 5 random high power fields. There were no significant differences between the groups in terms of age, total prostatic volume, resected prostatic weight, or prostate-specific antigen (PSA). RESULTS: The mean MVD in the suburethral portion in dutasteride-treated patients was significantly lower than that seen in untreated patients(14.47 versus 22.19 vessels per high power field, p=0.026). In nodular hyperplasia, there was no significant difference in MVD between the two group(14.72 versus 15.24 vessels per high power field, p=0.801). CONCLUSIONS: Short term pretreatment with dutasteride decreases suburethral prostatic MVD in patients with BPH and may help reduce blood loss during TURP, particularly in huge BPH, which sometimes bleeds excessively during operation.


Asunto(s)
Humanos , Azaesteroides , Vasos Sanguíneos , Finasterida , Hematuria , Hemoglobinas , Hiperplasia , Microvasos , Próstata , Antígeno Prostático Específico , Hiperplasia Prostática , Resección Transuretral de la Próstata , Dutasterida
2.
Korean Journal of Urology ; : 356-358, 2007.
Artículo en Coreano | WPRIM | ID: wpr-209682

RESUMEN

A primary signet ring cell carcinoma (PSRCC) of the urinary bladder is a rare variant of a mucin-producing adenocarcinoma. The prognosis of a PSRCC is poor, as silent progression in a linitis platica fashion leads to delayed diagnosis. Herein, the case of a PSRCC of the bladder, which extended to the prostate, which was treated with a cystoprostatectomy, is reported.


Asunto(s)
Adenocarcinoma , Carcinoma de Células en Anillo de Sello , Diagnóstico Tardío , Pronóstico , Próstata , Vejiga Urinaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA